Intrauterine Misoprostol Versus Rectal Misoprostol in Reducing Blood Loss During Cesarean Section

• Status: Recruiting
• Trial end date: 2020-05-15
• Target enrollment: 0
• Participant gender: Female

Summary

98 pregnant women attending for CS will be randomized into 2 groups. Rectal misopristol group who will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion and intrauterine misopristol group will receive 400 microgram misoprostol intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta. The estimated blood loss for each patient will be measured and data of both groups will be compared.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Misoprostol

Criteria

Inclusion Criteria:

• Pregnant women candidate for CS.

• Full term singleton living pregnancies (> 37 weeks confirmed by the 1st day of the LMP or 1st trimesteric ultrasound scan).

• Spinal or epidural anesthesia for the CS.

Exclusion Criteria:

• Maternal Anemia (hemoglobin <9 g%)

• Maternal medical disorders (e.g. cardiac, renal, and hepatic diseases, or coagulopathies).

• Fetal anomalies or IUGR (estimated fetal weight below the 5th centile)

• Risk of obstetric hemorrhage (e.g. peripartum hemorrhage, abnormal placentation, previous history of uterine atony or postpartum hemorrhage).

• Women attending for emergency CS.

• More than 2 previous CS procedures.

• Prolonged procedure (more than 2 hours from skin incision to skin closure).

• History of prostaglandin allergy.